SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 270 filers reported holding SAGE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,058 | -99.5% | 100 | -97.5% | 0.00% | -100.0% |
| Q3 2019 | $422,000 | -10.0% | 3,932 | +53.4% | 0.00% | -50.0% |
| Q2 2019 | $469,000 | +29.9% | 2,563 | +13.0% | 0.00% | +100.0% |
| Q1 2019 | $361,000 | +71.1% | 2,269 | +3.1% | 0.00% | 0.0% |
| Q4 2018 | $211,000 | +0.5% | 2,200 | +64.2% | 0.00% | 0.0% |
| Q2 2018 | $210,000 | +2525.0% | 1,340 | +1240.0% | 0.00% | – |
| Q2 2017 | $8,000 | +14.3% | 100 | 0.0% | 0.00% | – |
| Q1 2017 | $7,000 | +40.0% | 100 | 0.0% | 0.00% | – |
| Q4 2016 | $5,000 | -16.7% | 100 | -18.0% | 0.00% | – |
| Q3 2016 | $6,000 | -93.5% | 122 | -96.1% | 0.00% | -100.0% |
| Q2 2016 | $93,000 | +3000.0% | 3,100 | +3000.0% | 0.00% | – |
| Q1 2016 | $3,000 | -50.0% | 100 | 0.0% | 0.00% | – |
| Q4 2015 | $6,000 | +50.0% | 100 | 0.0% | 0.00% | – |
| Q3 2015 | $4,000 | -20.0% | 100 | 0.0% | 0.00% | – |
| Q1 2015 | $5,000 | +25.0% | 100 | 0.0% | 0.00% | – |
| Q4 2014 | $4,000 | +33.3% | 100 | 0.0% | 0.00% | – |
| Q3 2014 | $3,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |